NASDAQ: LPCNLipocine Inc Stock
$2.87-0.05 (-1.71%)
Updated May 13, 2025
LPCN Price
$2.87
Fair Value Price
$1.19
Market Cap
$15.36M
52 Week Low
$2.68
52 Week High
$11.79
P/E
-2.87x
P/B
0.8x
P/S
4.63x
PEG
N/A
Dividend Yield
N/A
Revenue
$3.67M
Earnings
-$5.37M
Gross Margin
100%
Operating Margin
-146.11%
Profit Margin
-146.1%
Debt to Equity
0.07
Operating Cash Flow
-$6M
Beta
0.86
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
LPCN Overview
Lipocine Inc., a clinical-stage biopharmaceutical company, focuses on the development of pharmaceutical products for the treatment of neuroendocrine and metabolic disorders. The company's primary development programs are based on oral delivery solutions for poorly bioavailable drugs. Its lead product candidate is TLANDO, an oral testosterone replacement therapy. The company's pipeline candidates also include LPCN 1144, an oral prodrug of bioidentical testosterone that has completed Phase II clinical trial for the treatment of non-cirrhotic non-alcoholic steatohepatitis; LPCN 1111, an oral prodrug of testosterone tridecanoate for once daily dosing, which has completed Phase II clinical trial in hypogonadal men; LPCN 1148, a novel prodrug of testosterone and testosterone laurate for the management of decompensated cirrhosis; LPCN 1154, an investigational new drug application to conduct a Phase 2 study in Postpartum depression; LPCN 2101 for women with epilepsy, which has completed pre-clinical study; and LPCN 1107, an oral hydroxyprogesterone caproate product that has completed dose finding Phase II clinical trial for the prevention of recurrent preterm birth. The company is headquartered in Salt Lake City, Utah.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine LPCN's potential to beat the market
- LPCN doesn't meet the minimum data requirements for our proprietary Zen Ratings model. Learn more about Zen Ratings.
Zen Rating Component Grades
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
LPCN
RankedUnranked of 453
RankedUnranked of 453
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $46.39 | A | |
| $7.82 | A | |
| $60.81 | A |
Be the first to know about important LPCN news, forecast changes, insider trades & much more!
LPCN News
Overview
Due Diligence Score
–
Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how LPCN scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
LPCN ($2.87) is overvalued by 141.59% relative to our estimate of its Fair Value price of $1.19 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
LPCN ($2.87) is not significantly undervalued (141.59%) relative to our estimate of its Fair Value price of $1.19 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
LPCN is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more LPCN due diligence checks available for Premium users.
Valuation
LPCN fair value
Fair Value of LPCN stock based on Discounted Cash Flow (DCF)
Price
$2.87
Fair Value
$1.19
Overvalued by
141.59%
LPCN ($2.87) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
LPCN ($2.87) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
LPCN is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
LPCN price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-2.87x
Industry
-164.79x
Market
25.53x
LPCN price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
0.8x
Industry
4.14x
LPCN is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
LPCN's financial health
Profit margin
Revenue
$93.9k
Net Income
-$1.9M
Profit Margin
-1,986.8%
LPCN's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
LPCN's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$20.5M
Liabilities
$1.3M
Debt to equity
0.07
LPCN's short-term assets ($20.33M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
LPCN's short-term assets ($20.33M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
LPCN's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
LPCN's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$2.0M
Investing
-$882.1k
Financing
$0.0
LPCN's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
LPCN vs Biotech Stocks
Lipocine Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.